Press Release


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Spectrum Pharmaceuticals Announces Second Quarter 2008 Corporate Update and Pipeline Review Conference Call

August 4, 2008 at 12:00 AM EDT
Spectrum Pharmaceuticals Announces Second Quarter 2008 Corporate Update and Pipeline Review Conference CallIRVINE, Calif.--(BUSINESS WIRE)--Aug. 4, 2008--Spectrum Pharmaceuticals, Inc., (NasdaqGM: SPPI) today announced Rajesh C. Shrotriya, M.D., Chairman, Chief Executive Officer, and President, and other members of senior management, will host a conference call and webcast to discuss second quarter 2008 operating results and provide a development update for its pipeline of drug candidates.
Tuesday, August 12, 2008 @ 12:00 p.m. Eastern/9:00 a.m. Pacific
  Domestic:            866-831-6272          passcode 37352497
  International:       617-213-8859          passcode 37352497

Webcast and replays:

Audio replays will be available through August 19, 2008.
  Domestic:            888-286-8010, passcode 39219118
  International:       617-801-6888, passcode 39219118

About Spectrum Pharmaceuticals

We are a biopharmaceutical company that acquires, develops and commercializes a diversified portfolio of drug products, with a focus mainly on oncology and urology. Our strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for our approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in developing drugs and commercialization in our areas of focus; and, leveraging the expertise of partners around the world to assist us in the execution of our strategy. For more information, please visit our website at

Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize its portfolio of drug candidates and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc., and FUSILEV™, TURNING INSIGHTS INTO HOPE™ and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.

© 2008 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

CONTACT: Spectrum Pharmaceuticals, Inc.
Russell Skibsted, SVP & Chief Business Officer
Paul Arndt, Manager, Investor Relations

SOURCE: Spectrum Pharmaceuticals, Inc.